{"commentary":{"count":39,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":14,"podcast":13,"youtube":12},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04793958\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT04793958","nct_id":"NCT04793958","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04793958. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":null,"arms":[{"description":null,"label":"MRTX849 + Cetuximab","type":"EXPERIMENTAL"},{"description":null,"label":"mFOLFOX6 or FOLFIRI","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-10-23","type":"ESTIMATED"},"conditions":["Advanced Colorectal Cancer","Metastatic Colorectal Cancer"],"enrollment":{"count":461,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"MRTX849","type":"DRUG"},{"name":"Cetuximab","type":"BIOLOGICAL"},{"name":"mFOLFOX6 Regimen","type":"DRUG"},{"name":"FOLFIRI Regimen","type":"DRUG"}],"last_update":"2026-09-28","lead_sponsor":"Mirati Therapeutics Inc.","official_title":"A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-01-16","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"30 months"},{"measure":"Progression-free Survival (PFS)","timeFrame":"30 months"}],"references":[{"citation":"Deming DA. Development of KRAS Inhibitors and Their Role for Metastatic Colorectal Cancer. J Natl Compr Canc Netw. 2025 Jan 3;23(1):e247067. doi: 10.6004/jnccn.2024.7067.","pmid":"39752885","type":"DERIVED"}],"start_date":{"date":"2021-06-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)","url":"https://clinicaltrials.gov/study/NCT04793958"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04793958"}